Using [18F]FDG PET/CT, the PD-L1 immune checkpoint inhibitor avelumab was associated with an increase in aortic TBRmax within 3 months after treatment initiation in patients with metastatic or irresectable Merkel cell carcinoma. This evidence concerns the gene CD274 and Merkel cell skin cancer.